<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<meta name="format-detection" content="telephone=no">
<title>teriparatide (rDNA origin) injection|FORTEO 骨穩©注射液 EDM#9</title>
<style>
html{
    background:#F8F6F5}
body{
    width: 100%;
	margin:0;
	padding:0;
    font-family:'Microsoft JhengHei','PingFangTC-Regular', 'Arial', 'Helvetica', sans-serif}
image{
	border:0}
</style>
</head>


<body>
    <table width="640" cellspacing="0" cellpadding="0" style="margin: 0 auto; background-color: #eee">
        <tr>
            <td>
                <img src="https://www.iprc.com.tw/edm/forteo/images/edm-09_01.png" width="640" height="158" style="display:block;outline:0;border:0" alt="FORTEO teriparatide (rDNA origin) injection">
            </td>
        </tr>
        <tr>
            <td>
                <img src="https://www.iprc.com.tw/edm/forteo/images/edm-09_02.png" width="640" height="69" style="display:block;outline:0;border:0" alt="Dear Doctors:">
            </td>
        </tr>
        <tr>
            <td>
                <img src="https://www.iprc.com.tw/edm/forteo/images/edm-09_03.png" width="640" height="118" style="display:block;outline:0;border:0" alt="Fractures Prevention is very important for osteoporosis treatment. ALAFOS study evaluated new clinical vertebral and non-vertebral fragility fractures in relation to time on teriparatide in postmenopausal women with osteoporosis in real-life clinical practice.">
            </td>
        </tr>
        <tr>
            <td>
                <img src="https://www.iprc.com.tw/edm/forteo/images/edm-09_04.png" width="640" height="132" style="display:block;outline:0;border:0" alt="*">
            </td>
        </tr>
        <tr>
            <td>
                <img src="https://www.iprc.com.tw/edm/forteo/images/edm-09_06.png" width="640" height="137" style="display:block;outline:0;border:0" alt="a.All Clinical Fractures and b.Clinical Vertebral Fractures">
            </td>
        </tr>
        <tr>
            <td>
                <img src="https://www.iprc.com.tw/edm/forteo/images/edm-09_07.png" width="640" height="171" style="display:block;outline:0;border:0" alt="chart part1">
            </td>
        </tr>
        <tr>
            <td>
                <img src="https://www.iprc.com.tw/edm/forteo/images/edm-09_08.png" width="640" height="143" style="display:block;outline:0;border:0" alt="c.Non-vertebral Fractures and d.Hip Fracturestures">
            </td>
        </tr>
        <tr>
            <td>
                <img src="https://www.iprc.com.tw/edm/forteo/images/edm-09_09.png" width="640" height="173" style="display:block;outline:0;border:0" alt="chart part2">
            </td>
        </tr>
        <tr>
            <td>
                <img src="https://www.iprc.com.tw/edm/forteo/images/edm-09_10.png" width="640" height="83" style="display:block;outline:0;border:0" alt="There was a statistically significant decrease in the rate of new clinical fractures during the >6 to 12-month, > 12 to 18-month, and >18 to 24 months periods.">
            </td>
        </tr>
        <tr>
            <td>
              <a href="https://link.springer.com/content/pdf/10.1007/s00223-021-00895-4.pdf" title="Find more here!" target="_blank">
                <img src="https://www.iprc.com.tw/edm/forteo/images/edm-09_11.png" width="640" height="90" style="display:block;outline:0;border:0" alt="learn more about reducing fracture risk?">
              </a>
            </td>
        </tr>
        <tr>
            <td>
                <img src="https://www.iprc.com.tw/edm/forteo/images/edm-09_12.png" width="640" height="172" style="display:block;outline:0;border:0" alt="Not only Fix the fracture but Treat the Osteoporosis">
            </td>
        </tr>
        <tr>
            <td>
                <img src="https://www.iprc.com.tw/edm/forteo/images/edm-09_13.png" width="640" height="112
                " style="display:block;outline:0;border:0" alt="骨穩。注射液 Forteo (teriparatide) For Injectian 適應症：停經後婦女骨質疏鬆症具高度骨折風險者、男性原發性或次發於性腺功能任下症之骨質疏縣症且具高度骨折風險者、女性及男性因糖化皮質類固醇治療引起之骨質疏縣症且具高度骨 折風險者。用法用量：建議劑量為 20 mcg 皮下注射一天一次 應注射於大腿或腹部。僅在病人仍慮於高度骨折風險或回復至高度骨折風險的狀態時，才考感在其一生中使用 FORTEO 超過2年。 禁忌：FORTEO 不可用於對 teriparatide 或其任何賦形劑有過敏反應的病人。過敏反應包括血管性水腫與過敏性反應等。警語及注意事項：骨肉瘤、高血鈣與皮腐鈣化、尿路結石的風險、姿勢性 低血壓、Digoxin 毒性的風險等。常見的不良反應(三 10%)：疼痛、關節痛等。詳細不良反應與注意事項請参照 Forteo’藥品說明書。骨穩”注射液 衛署菌疫輸字第 000787 號 台灣禮來股份有限公司台北市復興北路365號 11樓 以上為骨穩”注射液簡易仿單，請參見 Reference 1">
            </td>
        </tr>
        <tr>
            <td>
                <img src="https://www.iprc.com.tw/edm/forteo/images/edm-09_14.png" width="640" height="111" style="display:block;outline:0;border:0" alt="copyright">
            </td>
        </tr>
    </table>
</body>
</html>